SAN DIEGO, April 10, 2013 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQX ONVO) ("Organovo"), a creator and manufacturer of functional, three-dimensional human tissues for medical research and therapeutic applications, today provided a summary of the data it plans to present at the upcoming 2013 Experimental Biology conference in Boston, Massachusetts, from April 20-24.
The company plans multiple presentations at the conference. Dr. Sharon Presnell, Organovo chief technology officer, will give a presentation on rapid fabrication of architecturally-correct human tissues in vitro by 3D bioprinting. Individual projects to be additionally presented by Organovo scientists include data on Organovo's novel in vitro three-dimensional bioprinted liver tissue system for drug development, as well as data on Organovo's differentiation of bone tissue from 3D bioprinted constructs.
The presentation of 3D liver results marks the achievement of a milestone Organovo identified last year as a step towards launching a 3D liver assay in 2014, and Organovo remains on track towards achieving that goal. The company believes that a bioprinted 3D liver assay can provide superior results to current human cellular models and provide significant value to pharmaceutical researchers.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The company is working in collaboration with pharmaceutical and academic partners to develop human biological disease models in three dimensions that enable therapeutic drug discovery and development. Organovo's technology can also be applied to create surgical tissues for direct therapy. Their three-dimensional bioprinting technology was selected as one of the "Best Inventions of 2010" by TIME Magazine. Organovo leads the way in solving complex medical research problems and building the future of medicine. Visit www.organovo.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our annual report on Form 10-K filed with the SEC on March 15, 2013. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events.